On September 29th, Microsoft Research released an experimental multimodal AI research system called Project Quine. Essentially, it is a "world model" tailored for biology, aiming to connect computational biological modeling with real-world lab operations. This system was developed by Microsoft in collaboration with Harvard University and the Broad Institute of MIT and Harvard. It integrates genomics, proteins, chemistry, cell states, and biological imaging into a unified representation framework, combined with interactive reasoning capabilities, allowing it to process information from multiple fields and perform cross-model integration analysis.

image.png

To enable researchers to start using it as soon as possible, Microsoft has opened applications for the first Quine Fellows program. In the future, it will gradually expand through products such as Microsoft Discovery, offering more tools for industry use.

Potential and Boundaries Coexist

The biggest bottleneck in traditional drug development is limited resources and long cycles. Project Quine's approach is to first use algorithms to pre-screen candidate molecules and prioritize them, then allocate precious experimental resources to the most promising targets. Recently, Microsoft tested it on pancreatic ductal adenocarcinoma cell lines, and within just one weekend, it identified compounds that could shift the cell state from the classical type to the basal-like type, as well as some unexpected phenotypic responses. The company estimates that such tools could save years of time and millions of dollars, and even uncover treatment pathways previously unimaginable.

However, Microsoft has clearly defined boundaries: the system is currently only for research purposes and will not enter clinical use. All outputs must undergo strict manual review—after all, AI can still make mistakes.